Analysts Expect Marrone Bio Innovations Inc (NASDAQ:MBII) Will Post Quarterly Sales of $9.01 Million
Equities analysts expect Marrone Bio Innovations Inc (NASDAQ:MBII) to post $9.01 million in sales for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Marrone Bio Innovations’ earnings, with the highest sales estimate coming in at $10.10 million and the lowest estimate coming in at $7.92 million. Marrone Bio Innovations posted sales of $5.75 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 56.7%. The firm is scheduled to issue its next earnings report on Tuesday, August 13th.
On average, analysts expect that Marrone Bio Innovations will report full year sales of $31.66 million for the current year, with estimates ranging from $27.00 million to $36.52 million. For the next financial year, analysts anticipate that the company will post sales of $40.70 million, with estimates ranging from $34.00 million to $46.77 million. Zacks Investment Research’s sales averages are a mean average based on a survey of research firms that that provide coverage for Marrone Bio Innovations.
Marrone Bio Innovations (NASDAQ:MBII) last issued its earnings results on Thursday, May 9th. The basic materials company reported ($0.04) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.04). Marrone Bio Innovations had a negative net margin of 82.82% and a negative return on equity of 123.95%. The firm had revenue of $8.72 million during the quarter, compared to analysts’ expectations of $6.18 million.
Shares of Marrone Bio Innovations stock traded up $0.01 during trading on Friday, hitting $1.42. 45,999 shares of the company’s stock were exchanged, compared to its average volume of 79,893. The company has a quick ratio of 1.47, a current ratio of 1.94 and a debt-to-equity ratio of 2.47. The firm’s 50-day simple moving average is $1.47. Marrone Bio Innovations has a 52-week low of $1.10 and a 52-week high of $2.18. The company has a market cap of $157.23 million, a PE ratio of -6.76 and a beta of -0.08.
Institutional investors have recently modified their holdings of the stock. Paloma Partners Management Co acquired a new stake in Marrone Bio Innovations during the fourth quarter valued at $73,000. SG Americas Securities LLC acquired a new stake in Marrone Bio Innovations during the first quarter valued at $74,000. Spark Investment Management LLC grew its position in Marrone Bio Innovations by 47.5% during the first quarter. Spark Investment Management LLC now owns 95,000 shares of the basic materials company’s stock valued at $145,000 after buying an additional 30,600 shares during the period. Geode Capital Management LLC grew its position in Marrone Bio Innovations by 5.8% during the fourth quarter. Geode Capital Management LLC now owns 443,611 shares of the basic materials company’s stock valued at $652,000 after buying an additional 24,460 shares during the period. Finally, Rhumbline Advisers grew its position in Marrone Bio Innovations by 44.3% during the fourth quarter. Rhumbline Advisers now owns 68,021 shares of the basic materials company’s stock valued at $100,000 after buying an additional 20,882 shares during the period. 42.04% of the stock is owned by hedge funds and other institutional investors.
About Marrone Bio Innovations
Marrone Bio Innovations, Inc provides bio-based pest management and plant health products primarily for agricultural and water markets in the United States and internationally. It offers herbicides; fungicides; nematicides; insecticides; algaecides for algae control; molluscicides for mussel and snail control; plant growth and stress regulators; and water treatment products for various applications, such as hydroelectric and thermoelectric power generation, industrial applications, drinking water, aquaculture, irrigation, and recreation.
See Also: Trade War
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Marrone Bio Innovations Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marrone Bio Innovations and related companies with MarketBeat.com's FREE daily email newsletter.